23-190 Opiate Overdose Prevention and Treatment - Naloxone Hydrochloride

The San Francisco Police Department, partnered with the Department of Public Health (DPH), provides members with intranasal applications of Naloxone Hydrochloride (Naloxone). Similar to Automated External Defibrillators, the program intends to provide first responders with another tool that may potentially save lives.

Training
All current members have received training, and training will be provided for Recruits during the Basic Recruit Class. The training includes an overview of the laws allowing law enforcement officers to use Naloxone, causes of opiate overdose, victim assessment (e.g., signs/symptoms of overdose), universal precautions, rescue breathing, contacting appropriate emergency medical services, and the proper way to administer the intranasal Naloxone application.

The training has been incorporated in all AO/CPT cycles since January 2015. Additionally, the Video Production Unit produced a training video explaining and demonstrating the administering of Naloxone  redacted.

Deployment
Units not currently in receipt of Naloxone Hydrochloride may request issuance through Department Memorandum along with Supply Requisition form SFPD-95B. Submit these documents through the chain of command to your commanding officer for approval and forward to the Storeroom Supervisor at the Hall of Justice.

Procedure
When a member arrives at the scene of a medical emergency prior to the arrival of EMS/paramedics, the member shall take the following steps:

• Ensure that the scene is safe,
• Use universal precautions,
• Assess the need for medical treatment of the person consistent with Department policies, procedures and training, including taking statements from witnesses and/or family members regarding drug use,
• Request an ambulance,
• Provide first aid to the person consistent with first responder training, and
• Continue to observe and provide first aid until the ambulance arrives.

If a member determines that the person is suffering from an opiate overdose, the member is authorized to administer Naloxone consistent with the training provided by the San Francisco Police Academy and DPH. Only members trained in the use of the Naloxone are authorized to administer the medication.

Upon arrival of EMS/paramedics, the administering member shall inform EMS/paramedics that they have administered Naloxone. The member shall give the used intranasal Naloxone device to EMS/paramedics for disposal.

Reporting Requirements/Commendation Recommendations
If Naloxone is administered, the member shall submit an incident report in Crime Data Warehouse or ILEADS using at least one type of incident entitled: Aided Case - Naloxone Deployment (51050).

The incident report shall detail the nature of the incident (on-view or dispatched, type of call, etc.), the care the person received, how it was determined that there was a suspected opiate overdose, the fact that the Naloxone was administered, the number of doses, the outcome of the application, and the name and identification number of the EMS/paramedic provider who took control of the used intranasal Naloxone vial.

The Commanding Officer shall evaluate for an appropriate commendation recommendation (Life Saving Award, Captain's Comp, etc.).

In addition to the normal procedure for submitting reports, the OIC shall ensure that a copy of the report is emailed to the Health & Safety Manager in the Medical Liaison Unit at: redacted

Maintenance/Replacement
Station facility coordinators are responsible for the maintenance and upkeep of the Naloxone kits and shall damaged, expired or used Naloxone kits to the Staff Services Division at redacted for replacement.

Members with questions about the Naloxone program may contact the Police Academy staff at redacted

/s/
WILLIAM SCOTT 
Chief of Police

Per DN 23-152, all sworn & non-sworn members shall electronically acknowledge this Department document in PowerDMS within (30) thirty calendar days of issuance. Members whose duties are relevant to this document shall be held responsible for compliance. Any questions regarding this policy should be sent to [email protected] who will provide additional information.